HIV-positive women with CMV in their urine at the time of labor and delivery are more than five times likelier than HIV-positive women without CMV to transmit HIV to their infants. The research also found that they are nearly 30 times likelier to transmit CMV to their infants.
For decades, HIV has successfully evaded all efforts to create an effective vaccine but researchers at The Scripps Research Institute (TSRI) and the La Jolla Institute for Allergy and Immunology (LJI) are steadily inching closer. Their latest study, published in the current issue of Immunity, demonstrates that optimizing the mode and timing of vaccine delivery is crucial to inducing a protective immune response in a preclinical model.
Understanding and responding to behavioral trends in groups that are at high risk for HIV infection is critical to the development of effective strategies that decrease HIV incidence and improve access to care. New research based on data from the Centers for Disease Control and Prevention’s National HIV Behavioral Surveillance (NHBS) system are presented in a special supplement to JAIDS: Journal of Acquired Immune Deficiency Syndromes. The journal is published by Wolters Kluwer.
A plant found throughout Southeast Asia traditionally used to treat arthritis and rheumatism contains a potent anti-HIV compound more powerful than the drug AZT, according to a new paper published in the Journal of Natural Compounds.
New York State International Training and Research Program Receives $1.5 Million to Conduct HIV Research Training Program in Ukraine
The National Institutes of Health has awarded researchers at Albert Einstein College of Medicine, The Rockefeller University, The City University of New York Graduate School of Public Health and Health Policy (CUNY), a $7.5 million grant for the Center for AIDS Research focused on preventing HIV transmission and ending the AIDS epidemic.
Researchers from Penn Medicine have developed a new urine test, called UrSure, to monitor adherence to pre-exposure prophylaxis (PrEP) in order to help curb the HIV epidemic and prevent high-risk populations from being infected with HIV.
Building on insights from an HIV vaccine regimen in humans that had partial success during a phase 3 clinical trial in Thailand, a Duke-led research team used a more-is-better approach in monkeys that appeared to improve vaccine protection from an HIV-like virus.
Ask Elizabeth Bowen about the intersection of homelessness and HIV/AIDS in the United States and she’ll respond without hesitation, “Housing equals health.”
Researchers at Johns Hopkins Medicine report new evidence that immune cells infected with a latent form of human immunodeficiency virus (HIV) are able to proliferate, replenishing the reservoir of virus that is resistant to antiretroviral drug therapy. Although HIV can be controlled with therapy in most cases, the proliferation of such reservoir cells pose a persistent barrier to developing a cure for HIV, researchers say.
Scientists at The Scripps Research Institute (TSRI) have made another important advance in HIV vaccine design.
A new cost-benefit analysis conducted by the Johns Hopkins Bloomberg School of Public Health and others suggests that $6 million in costs related to the opioid epidemic could be saved each year if a single “safe consumption” space for illicit drug users were opened in Baltimore.
Adherence to care improves when youth with HIV receive education and help navigating the system, according to study out of UAB.
News release about promising research
A special issue of the Journal of Infectious Diseases focuses solely on HIV eradication and is edited by the director of the UNC HIV Cure Center in Chapel Hill.
The criminalization of drug use has a negative effect on efforts to prevent the spread of HIV and to treat people with the infection, suggests a review of published research conducted by the Johns Hopkins Bloomberg School of Public Health and the University of British Columbia.
The United States could be on track within the next decade to see significant steps towards ending the HIV epidemic in this country, suggests new research from the Johns Hopkins Bloomberg School of Public Health and Brigham and Women’s Hospital.
A permanent cure for HIV infection remains elusive due to the virus's ability to hide away in latent reservoirs.
UAB researchers develop a conceptual framework to help progress the care of people living with HIV by looking at ways to pursue better engagement in care.
Nigel Poor is producing a podcast about life in prison.
Men who have sex with men (MSM) accounted for two thirds of all new HIV infections in the United States, with 26 percent occurring in Latinos, according to 2014 data. If those rates continue, it is estimated that one in four Latino MSM may be diagnosed with HIV during his lifetime.
According to the most recent statistics from the Centers for Disease Control and Prevention, 22 percent of new HIV diagnoses in the United States in 2014 occurred among young people ages 13 to 24, 80 percent of whom were gay and bisexual males.
A new study finds defective HIV proviruses, long thought to be harmless, produce viral proteins and distract the immune system from killing intact proviruses needed to reduce the HIV reservoir and cure HIV. The study was published by researchers at the George Washington University and Johns Hopkins University in Cell Host & Microbe.
Researchers at Johns Hopkins and George Washington universities report new evidence that proteins created by defective forms of HIV long previously believed to be harmless actually interact with our immune systems and are actively monitored by a specific type of immune cell, called cytotoxic T cells.
Starting in the 2017-18 school year, two Rush neurology residents will complete a one-month rotation in Zambia, Africa, each year as part of a new elective rotation run by Dr. Igor Koralnik, chairperson of the Department of Neurological Sciences at Rush Medical College and chief of the Section of Neuroinfectious Diseases.
A UNC research team has identified a new cell in the body where HIV persists despite treatment. This discovery has major implications for cure research.
Investigators examined the relationship between injection drug use and immune activation in a sample of HIV infected and uninfected PWID. Findings suggest that efforts to encourage injection cessation or reduction in frequency can have positive health benefits through reducing immune activation.
Professor Michael Farzan, co-chair of the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute (TSRI) has received $4.8 million in funding through a 2017 Avant-Garde Award for HIV/AIDS research from the National Institutes of Health’s National Institute on Drug Abuse (NIDA). The new funding will support a five-year project, led by Farzan, to bring a potential HIV vaccine closer to human clinical trials.
The study, ”The Committed Inmate Relationships During Incarceration and STI/HIV Prevention,” aimed to characterize the relationships of incarcerated African-Americans and the influence of those characteristics in protection against STI/HIV risk when in the community, when STI/HIV transmission risk is greatest.
Scientists at The Scripps Research Institute (TSRI) have found a way to tether HIV-fighting antibodies to immune cells, creating a cell population resistant to the virus.
The University of Chicago Medicine's Center for Interdisciplinary Inquiry and Innovation (Ci3) in Sexual and Reproductive Health has launched a research initiative aimed at reducing HIV infection and transmission among vulnerable youth of color, including young men who have sex with men (YMSM) and young transgender women.
Using computational tools inspired by financial math models developed to predict changes in stock prices, University of Iowa researchers were able to accurately predict how different properties of the HIV surface protein (Env) evolved in the population of Iowa over the course of 30 years. The ability to predict such changes by testing a small number of patients could potentially allow tailoring of vaccines to the specific forms of HIV present in different populations worldwide.
More than a third of HIV patients develop oral conditions from immune systems compromised by the virus and its treatment, according to the National Institutes of Health (NIH)
Researchers from UNC-Chapel Hill, the National Cancer Institute and Centers for Disease Control and Prevention, reported preliminary findings at the American Association for Cancer Research Annual Meeting April 5 that the total number of HIV-positive cancer patients in the United States is projected to decrease through 2030. The researchers also projected that there would be a decrease in cancers linked to the advanced stage of HIV infection -- AIDS.
A new study examines what young adults in Balaka, Malawi think about how anti-retroviral drugs are distributed amid an AIDS epidemic in the African nation.
Researchers at the School of Medicine are hoping that the power of the internet – and compelling personal experiences – will help reach people with HIV who are neglecting their health because of fear, stigma or substance abuse. The researchers are testing an online program they have developed to address the problems they see most commonly among people who are failing to take their HIV medications.
Top experts from the government, non-profit and media sphere will address past, present and future contagious threats in an afternoon-long event at the University of Michigan.
Statistical mapping technique shows widely dispersed population could pose challenges for initiative
According to the most recent statistics from the Centers for Disease Control and Prevention, 22 percent of new HIV diagnoses in the United States in 2014 occurred among young people ages 13 to 24, 80 percent of whom were gay and bisexual males.
Scientists at The Scripps Research Institute (TSRI) have developed a method to analyze the glycan shield on HIV’s protective outer glycoprotein, developed as a potential HIV vaccine candidate.
Could unique psychological factors that hamper emotional regulation help explain differences in HIV/STI risk-related sexual behaviors among heterosexually active black youth with mental illnesses?
Researchers at the University of North Carolina at Chapel Hill have received a three-year, $1.8 million grant from the National Institutes of Health to develop a new implantable drug delivery system for long-lasting HIV-prevention.
Building on earlier work in designing chimeric human-simian immunodeficiency viruses (SHIVs) that serve as a model of HIV infection of humans, George M. Shaw, MD, PhD, a professor of Hematology/Oncology and Microbiology in the Perelman School of Medicine at the University of Pennsylvania, has received $16.3 million over five years from the National Institute of Allergy and Infectious Diseases to develop a long-sought-after HIV vaccine.
A Duke Health-led research team has described both the pathway of HIV protective antibody development and a synthetic HIV outer envelope mimic that has the potential to induce the antibodies with vaccination.
Computer model shows what happens at the molecular level during severe allergic reactions to abacavir, a common HIV drug
Increased longevity of those living with HIV means dealing with related health issues, including dementia and other cognition-related problems. An NIH grant supports development of interventions, treatments to improve everyday functioning, and quality of life.
Using antibodies to treat disease has been one of the great success stories of early 21st-century medicine. Already five of the ten top-selling pharmaceuticals in the United States are antibody products. But antibodies are large, complex proteins that can be expensive to manufacture. Now, a team led by scientists from the Perelman School of Medicine at the University of Pennsylvania demonstrates in an animal model a new way to deliver safer and more cost-effective therapeutic antibodies.
• From 2001 to 2012, HIV+ kidney failure patients on the transplant waiting list were 28% less likely to receive a transplant compared with their HIV- counterparts. • They were half as likely to receive a kidney from a living donor.
Professor of sociology Matt G. Mutchler’s research over the past 20 years into HIV prevention and treatment issues, especially within the African American community, has garnered him more than 15 external research awards and respect as an expert in the field.
Cervical cancer is the leading cause of cancer deaths for women low- and middle-income countries, including Botswana, where 75 percent of cervical cancer patients suffer from advanced forms of the disease. These patients can face wait times as long as five months after diagnosis before receiving lifesaving treatment. A new, multidisciplinary model of cervical cancer care developed by a University of Pennsylvania team based in Botswana cut the delay between diagnosis and treatment by more than 50 percent, according to research published this month in the Journal of Global Oncology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right